

Date of preparation: 2020-03-16

Abbreviated name of the Issuer:

MABION S.A.

Subject matter:

Arrangements for financing the Company's operations in light of the new regulatory strategy for registration of MabionCD20 in the EMA

Legal basis:

Article 17(1) MAR - confidential information.

Content of the report:

The Management Board of Mabion S.A. ("The Company") hereby informs that on March 16th, 2020, a meeting of the Supervisory Board was held also attended by representatives of the Management Board of the Company, during which a discussion was undertaken on financing the Company's operations in light of the new regulatory strategy for registration of MabionCD20 in the EMA.

Today, the Company's Management Board received supporting documents from the main shareholders who are the founders of the Company ("Shareholders"), according to which the Shareholders declared to supply capital to the Company in an amount not lower than PLN 15 million in 2020. The capital injection, in accordance with the Shareholders' declaration of March 16th, 2020, will take place in 2020 in tranches in accordance with the Company's financial needs. In line with the declarations, the injection may take place by taking up new issue shares or using debt instruments.

The Management Board of the Company approved the supporting documents from the Shareholders and decided to proceed to activities aimed at obtaining debt financing, which will enable effective implementation of the new strategy of registration for MabionCD20 in the EMA.

In the opinion of the Company's Management Board, it should be possible to obtain external debt financing thanks to the strong support the Board received from the Company's major shareholders. The capital supply and debt financing should ensure that the medicine in consideration will be admitted to trading both in the EU and in the USA.

In addition, the Company does not preclude seeking and using other sources of funding such as grants, subsidies from European Union funds, targeted funds for new projects or other options depending on the Company's needs and capabilities.